

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Laparoscopic versus open left hemicolectomy for left-sided colon cancer: protocol for a systematic review and meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-062216
Article Type:	Protocol
Date Submitted by the Author:	19-Feb-2022
Complete List of Authors:	Du, Qiang; Sichuan University West China Hospital, Department of Gastrointestinal Surgery Yang, Yang; Sichuan University West China Hospital, Department of Gastrointestinal Surgery Zhang, Jianhao; Sichuan University West China Hospital, Department of Gastrointestinal Surgery Liu, Xueting; Sichuan University West China Hospital, Department of Evidence-Based Medicine and Clinical Epidemiology Wang, Yong; Sichuan University West China Hospital, Department of Gastrointestinal Surgery Yang, Lie; Sichuan University West China Hospital, Department of Gastrointestinal Surgery; Sichuan University West China Hospital, Institute of Digestive Surgery, State Key Laboratory of Biotherapy and Cancer Center
Keywords:	Colorectal surgery < SURGERY, Gastrointestinal tumours < ONCOLOGY, SURGERY

SCHOLARONE™
Manuscripts

1
2
3
4
5
6 **Laparoscopic versus open left hemicolectomy for left-sided colon**
7
8
9 **cancer: protocol for a systematic review and meta-analysis**
10

11
12 Qiang Du^{#1}, Yang Yang^{#1}, Jianhao Zhang¹, Xueting Liu², Yong Wang^{1*}, Lie Yang^{1,3*}
13

14 ¹Department of Gastrointestinal Surgery, West China Hospital of Sichuan University, No. 37
15 Guoxue Lane, Chengdu, 610041, Sichuan Province, China.
16

17
18
19 ²Department of Evidence-Based Medicine and Clinical Epidemiology, West China Hospital of
20 Sichuan University, No. 37 Guoxue Lane, Chengdu, 610041, Sichuan Province, China.
21

22
23
24 ³Institute of Digestive Surgery, State Key Laboratory of Biotherapy and Cancer Center, West
25 China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.
26

27
28 **#Contributed equally to this manuscript.**
29

30
31 ***Corresponding author:**
32

33 Lie Yang, Department of Gastrointestinal Surgery, West China Hospital of Sichuan University,
34 No. 37 Guoxue Lane, Chengdu, 610041, China; Institute of Digestive Surgery, State Key
35 Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu,
36 610041, Sichuan, China; Tel: +86 28 85164035; Fax: +86 28 85164035; E-mail:
37
38
39 lie_222@163.com.
40
41
42

43
44 Yong Wang, Department of Gastrointestinal Surgery, West China Hospital of Sichuan University,
45 No. 37 Guoxue Lane, Chengdu, 610041, China. E-mail :wydoctor1974@aliyun.com.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction: Laparoscopic colectomy has been widely used clinically due to its minimally invasive advantages, and many studies have also demonstrated its safety and efficacy. However, the efficacy of laparoscopic left hemicolectomy remains unclear due to the differences in pathogenesis and surgical details between left and right colon cancers. Therefore, we plan to conduct a systematic review and meta-analysis to investigate whether laparoscopic techniques can be safely used in left hemicolectomy.

Method and analysis: This meta-analysis protocol will be completed and reported according to PRISMA-P (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols) guidelines. A systematic search was performed for all articles related to laparoscopic left hemicolectomy in PubMed, Web of Science, Medline, EMBASE, and the Cochrane Library from inception to November 5, 2021. Article screening and data extraction were performed independently by two authors and cross-checked after completion. The literature to be included will use corresponding tools for bias risk assessment. Subgroup analyses and sensitivity analyses will be used to explore potential heterogeneity.

Ethics and dissemination: Because this systematic review is based on studies with published results and does not involve intervention in patients, no ethical review is required. The results of this study will be published in a peer-reviewed journal.

PROSPERO registration number: CRD42022291526.

Strength and limitations of this study:

To the best of our knowledge, this will be the first meta-analysis to compare surgical approaches for left hemicolectomy.

Subgroup and sensitivity analyses will be used to explore potential heterogeneity.

Both the quality of the included literature and the final outcomes will be evaluated.

Restriction of publication language to English only is a limitation of this study.

INTRODUCTION

Colorectal cancer (CRC) is the third most commonly diagnosed malignant tumor and the third leading cause of tumor-related deaths worldwide.^{1 2} At present, surgery is still the main treatment for CRC, and laparoscopic surgery has become widely accepted due to its minimally invasive advantages. Although laparoscopic rectal cancer surgery remains controversial, laparoscopic colon cancer surgery has been recommended early by the National Comprehensive Cancer Network (NCCN) guidelines,³ mainly based on several large multicenter RCTs, including the Australasian Laparoscopic Colon Cancer Study (ALCCaS) Trial,⁴ the Clinical Outcomes of Surgical Therapy (COST) study,⁵ the Medical Research Council Conventional versus Laparoscopic-Assisted Surgery In Colorectal Cancer (MRC CLASICC) trial and the Colon Cancer Laparoscopic or Open Resection (COLOR) Study.^{6 7} These trials have demonstrated that laparoscopic colectomy is superior to conventional open surgery in terms of short-term outcomes, such as surgical incision length, intraoperative bleeding, and postoperative functional recovery, while also demonstrating that the adequacy of tumor removal is not threatened and that tumor-related long-term outcomes are not significantly different from those of open surgery.⁸⁻¹¹ In addition, these results have also been verified by the Cochrane Database of Systematic Reviews.^{12 13}

However, left-sided colon cancer has been underrepresented in these trials, as the patients who underwent left hemicolectomy accounted for a very low proportion in the included cases, such as 113 (10.4%) in the COLOR study,^{10 59} (7.4%) and 64 (7.4%) in the CLASICC trial and COST study,^{5 7} respectively, and even fewer in the ALCCaS and Barcelona trials, with only 22 (3.7%) and 5 (2.3%),^{11 14} respectively. Compared to right hemicolectomy or transverse colectomy, left hemicolectomy has quite different anatomic features and surgical procedures, with a challenge in the mobilization of splenic flexure. Furthermore, it has been widely accepted that right and left colon cancers are two different diseases based on their differences in embryonic origin, genetic characteristics, and biological behaviors and therefore may have different survival outcomes.¹⁵⁻¹⁸ Therefore, the safety and prognosis of the treatment of left and right colon cancer should be evaluated separately by site, but the existing clinical trials are not representative of left hemicolectomy, so there is an urgent need to study

1
2
3
4 this topic.

5
6 At present, several clinical trials have been conducted specifically on laparoscopic left
7 hemicolecotomy,^{19 20} and even results from RCTs have been published,^{21 22} but these results
8 lack a pooling to form evidence-based medical evidence. Therefore, the purpose of this study
9 was to synthesize the published results to fill the evidence gap for laparoscopic techniques for
10 left hemicolecotomy and to remind future investigators conducting colon cancer-related studies
11 to stratify the final results based on the different locations of the tumor if there are
12 inconsistencies between the results of this study and those of the whole colon.
13
14
15
16
17
18
19

20 21 **MATERIALS AND METHODS**

22
23 This meta-analysis protocol will be completed and reported according to PRISMA-P
24 (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols)
25 guidelines.^{23 24} According to the guidelines, our study has been registered on the website of
26 the International Prospective Register of Systematic Reviews (PROSPERO).²⁵ The
27 registration number is CRD42022291526.
28
29
30
31
32
33
34

35 **Inclusion criteria:**

36
37 Population: All patients with left-sided colon cancer confirmed by preoperative imaging and
38 pathology who underwent left hemicolecotomy with mobilization of splenic flexure were the
39 target population of our study.
40
41
42

43
44 Intervention: The intervention in the experimental group was laparoscopic left
45 hemicolecotomy. In this meta-analysis, the definition of left hemicolecotomy mainly included
46 four aspects. First, ligation of the corresponding vessels, such as the inferior mesenteric vein
47 (IMV), was performed. Second, mobilization and pull-down of splenic flexure were observed.
48 Third, resection of the distal transverse colon, splenic flexure, descending colon, sigmoid, etc.
49 Finally, either an intracorporeal anastomosis or an extracorporeal anastomosis is performed
50 for colocolonic anastomosis or colorectal anastomosis. Slight adjustments during the
51 procedure to suit the actual situation are considered acceptable.
52
53
54
55
56
57
58
59
60

1
2
3
4 Comparison: Traditional open left hemicolectomy.
5

6 Outcome: The outcomes assessed in this systematic review and meta-analysis included
7 perioperative outcomes (operative time, estimated blood loss, length of incision, time to
8 resume oral diet, time to peristalsis), postoperative outcomes (length of hospital stay, number
9 of harvested lymph nodes, 30-day mortality, postoperative complications), and oncological
10 outcomes (tumor recurrence, 5-year overall survival, and 5-year disease-free survival). In this
11 study, oncologic outcomes were considered primary outcomes, with perioperative and
12 postoperative outcomes as secondary outcomes.
13
14
15
16
17
18
19

20 Study design: All randomized controlled and nonrandomized controlled clinical studies
21 comparing laparoscopic left hemicolectomy with open left hemicolectomy for which full text
22 was available were included.
23
24
25
26

27 **Exclusion criteria:**

- 28
29
30 1. Studies that included tumors from other colorectal locations but did not analyse the left
31 hemicolectomy separately or for which data from the left hemicolectomy were not extractable
32 were not included.
33
34 2. Benign colorectal disease or emergency surgery will be excluded.
35
36 3. No splenic flexure mobilization will also be excluded.
37
38 4. Noncomparative studies and non-English publications were excluded.
39
40
41
42

43 **Study Selection**

44
45
46 We systematically searched the PubMed, Web of Science, Medline, EMBASE, and Cochrane
47 Library databases for all literature comparing laparoscopic and open surgical approaches for
48 left hemicolectomy from inception to November 5, 2021. Searches were carried out using
49 medical subject headings (MeSH) and free text words in combination with the search
50 strategy. We used the following keywords: “colon cancer”, “left hemicolectomy”,
51 “laparoscopy” and “open”. All possible forms of these keywords will be used to ensure the
52 comprehensiveness of the search. Additionally, we enriched our retrieval results with several
53 methods, such as the similar articles function in PubMed, cross-checking references of the
54
55
56
57
58
59
60

retrieved literature, searching ClinicalTrials (<https://www.clinicaltrials.gov/>), etc.

Search Terms for PubMed

#1 (((((((((((((((((((Colonic Neoplasms) OR (Neoplasm, Colonic)) OR (Neoplasms, Colonic)) OR (Colon Neoplasms)) OR (Colon Neoplasm)) OR (Neoplasm, Colon)) OR (Neoplasms, Colon)) OR (Cancer of Colon)) OR (Colon Cancers)) OR (Colon Cancer)) OR (Cancer, Colon)) OR (Cancers, Colon)) OR (Cancer of the Colon)) OR (Colonic Cancer)) OR (Cancer, Colonic)) OR (Cancers, Colonic)) OR (Colonic Cancers)) OR (Colon Adenocarcinoma)) OR (Adenocarcinoma, Colon)) OR (Adenocarcinomas, Colon)) OR (Colon Adenocarcinomas)

#2 open surgery

#3 (((((((((((((((Laparoscopy) OR (Celioscopy)) OR (Peritoneoscopy)) OR (Surgical Procedures, Laparoscopic)) OR (Laparoscopic Surgical Procedure)) OR (Procedure, Laparoscopic Surgical)) OR (Procedures, Laparoscopic Surgical)) OR (Surgery, Laparoscopic)) OR (Laparoscopic Surgical Procedures)) OR (Laparoscopic Surgery)) OR (Laparoscopic Surgeries)) OR (Surgeries, Laparoscopic)) OR (Laparoscopic Assisted Surgery)) OR (Laparoscopic Assisted Surgeries)) OR (Surgeries, Laparoscopic Assisted)) OR (Surgery, Laparoscopic Assisted)) OR (Surgical Procedure, Laparoscopic)

#4 (left hemicolectomy) OR (left colectomy)

#5 #2 AND #3

#6 #1 AND #4 AND #5

The management of the literature search records will be carried out in EndNote X9.1. Two authors (QD and JZ) independently performed an initial screening of the titles and abstracts of the search results and assessed the eligibility of the articles. After removing duplicates and irrelevant literature, the two authors will assess the eligibility of the articles according to the inclusion criteria after reading the full text of the remaining articles separately. Any controversial points arising during this process will be referred to a third author (LY) and discussed until the dispute is resolved. The specific literature screening process will be summarized in a flow diagram.

Data Extraction

Data to be collected, such as study details (first author, year of publication, study design, follow-up period, type of outcome), patient demographics (age, sex, American Society of Anesthesiologists (ASA) score, tumor stage, etc.), and the outcomes of interest mentioned above will be consolidated into a piloting spreadsheet. Additionally, we will extract the effect estimates of the outcome of interest for statistical analysis. If there were multiple representations of the data, we preferred to use the data after adjusting for confounding factors. To reduce bias and reduce errors in data extraction, the same two investigators (QD and JZ) independently extracted data from the included literature, cross-checked after extraction, and disagreements were resolved by discussion and, if necessary, by asking a third author (LY) to resolve. Because this analysis was based on the intention-to-treat principle, all patients who were converted from the laparoscopic group to the conventional open surgery group remained in the laparoscopic group for analysis. We will also use sensitivity analyses to assess the impact of including studies that do not report intention-to-treat on overall outcomes.

There are currently several RCTs, such as COST, CLASICC, ALCCaS, and COLOR, comparing laparoscopic and open colectomy, and we believe that inclusion of their data would enhance the quality of our evidence for this study. We will be sending emails to the authors of these trials asking for stratified data on left hemicolectomy.

Statistical Analysis

Statistically, it is not possible to combine the median with the mean value, and only data expressed as the mean and standard deviation can be used for meta-analysis. In this study, we will not use the median to estimate the mean, as other studies have done, because we believe this would not be worth the cost. The weighted mean difference (WMD) or standardized mean difference (SMD) and corresponding 95% confidence interval (CI) were used for the analysis of continuous variables. The dichotomous variables were analysed using risk ratio (RR) values with 95% CIs. Considering the characteristics of survival analysis, we will first

1
2
3
4 attempt to extract survival analysis-related data from the included studies and then calculate
5 the pooled hazard ratio (HR). HR and 95% CI will be extracted directly from the article, and
6 if not reported in the article, we consider using software such as Engauge Digitizer to obtain
7 the required data from Kaplan–Meier curves following the method provided by Parmar et al.²⁶
8 Finally, the obtained data will be integrated into the spreadsheet designed by Tierney et al. to
9 calculate the HR and 95% CI.²⁷ If the data were insufficient or the HR was not available for
10 other reasons, then the pooled OR values of OS and DFS were calculated separately.

11
12
13
14
15
16
17
18 Statistical heterogeneity among the studies was calculated by the chi-squared (χ^2) test and
19 I-squared (I^2) test.²⁸ We considered that high heterogeneity existed if the value of $P < 0.1$ or
20 $I^2 > 50\%$. If there was high heterogeneity, a random-effects model was applied. Otherwise, a
21 fixed-effects model was used. We will conduct subgroup analyses based on different study
22 design types so that we can explore the potential causes of heterogeneity and reduce it as
23 accurately as possible. Sensitivity analysis will be performed to determine the robustness of
24 the results by sequentially excluding one study at a time. $P < 0.05$ was considered statistically
25 significant. Software such as RevMan 5.4 and STATA 16 will be used for statistical
26 processing. Publication bias will be estimated by visual assessment of funnel plots if ≥ 10
27 studies are available. If the extracted data are not suitable for pooling, a systematic narrative
28 synthesis will be presented in textual form.

40 **Risk Of Bias Assessment**

41
42
43
44 Quality assessment will be carried out by two authors (QD and JZ), and discrepancies will be
45 resolved through discussion. If consensus was not reached, then the third author (LY) was
46 consulted for arbitration. The risk of bias in randomized controlled trials will be assessed
47 using the Cochrane Risk of Bias Tool,²⁹ which includes six aspects: randomization, allocation
48 concealment, application of blinding, integrity of outcome data, selective reporting, and other
49 biases. For each, we will use high risk, low risk, or unclear risk to assess the results. The
50 methodological quality of nonrandomized controlled trials will be evaluated using the
51 Newcastle–Ottawa Scale (NOS),³⁰ which consists of three aspects: patient selection,
52 comparability of cohorts, and assessment of outcome. The total score is 9 stars, and each
53
54
55
56
57
58
59
60

1
2
3 article is classified as low quality (0-5 stars) or high quality (6-9 stars). The final results will
4 be summarized in a table.
5
6
7

8 **Evidence Quality Evaluation**

9
10
11 The quality of evidence for each outcome will be evaluated using the Grading of
12 Recommendations Assessment, Development and Evaluation (GRADE) system,³¹ with four
13 levels: high, moderate, low, and very low.
14
15
16
17

18 **Patient And Public Involvement**

19
20 Since this study is a secondary study based on other studies, there will be no direct patient or
21 public involvement in this study.
22
23
24
25

26 **Ethics And Dissemination**

27
28 Because no patients were involved, ethical approval was not required. The final results of this
29 research will be submitted to a peer-reviewed journal or presented at relevant conferences,
30 and any deviations from this protocol will be recorded and explained in the final report.
31
32
33
34
35
36

37 **SUMMARY**

38
39 It has been more than 30 years since laparoscopic technology was first applied to colorectal
40 surgery.³² Although the risk of incomplete tumor removal was once questioned, laparoscopic
41 technology has particularly unique advantages over traditional open surgery and is now
42 widely used in clinical practice. However, in the existing studies, the proportion of left
43 hemicolectomy is very small, which is not enough to support the application of laparoscopy in
44 left colon cancer. Our review will provide a reference for the clinical use of laparoscopic left
45 hemicolectomy.
46
47
48
49
50
51
52
53

54 There may also be some limitations in our review. First, as the types of studies included
55 include both RCTs and non-RCTs, there is a high potential for heterogeneity between studies.
56
57 Second, we include only studies published in English, and we may have lost data published in
58
59
60

1
2
3
4 other languages to some extent, resulting in bias.
5

6 **Contributors:** The original idea was conceived by LY. QD and YY drafted the manuscript for
7 this protocol. QD, YY, JHZ, YW, LY participated in the design of the study and the setting of the
8 inclusion and exclusion criteria. QD and YY design the search strategy, and XTL will be
9 responsible for the modifications. QD and JHZ will perform the literature screening and data
10 extraction. YW and LY will review the overall work. All authors have read and approved the
11 publication of the protocol.
12
13
14
15
16

17
18 **Funding:** This work was supported by Wu Jieping Medical Foundation (No.312180452).
19

20
21 **Competing interests:** None declared.
22

23
24 **Ethical approval:** Not required.
25

26
27 **Patient consent for publication:** Not required.
28

29
30 **Provenance and peer review:** Not commissioned; externally peer reviewed.
31

32
33 **Open access:** This is an open access article distributed in accordance with the Creative Commons
34 Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix,
35 adapt, build upon this work non-commercially, and license their derivative works on different
36 terms, provided the original work is properly cited, appropriate credit is given, any changes made
37 indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.
38
39
40

41 42 **ORCID iDs**

43
44 Qiang Du: <https://orcid.org/0000-0002-7283-1140>
45

46
47 Lie Yang: <https://orcid.org/0000-0003-1178-7147>
48

49
50 **Word count** 2140
51

52 53 **REFERENCES**

- 54
55
56 1. Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021. *CA Cancer J Clin* 2021;71(1):7-33.
57 doi: 10.3322/caac.21654 [published Online First: 2021/01/13]
58 2. Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020. *CA Cancer J Clin*
59 2020;70(3):145-64. doi: 10.3322/caac.21601 [published Online First: 2020/03/07]
60

3. Benson AB, Venook AP, Al-Hawary MM, et al. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2021;19(3):329-59. doi: 10.6004/jnccn.2021.0012 [published Online First: 2021/03/17]
4. Hewett PJ, Allardyce RA, Bagshaw PF, et al. Short-Term Outcomes of the Australasian Randomized Clinical Study Comparing Laparoscopic and Conventional Open Surgical Treatments for Colon Cancer. *Annals of Surgery* 2008;248(5):728-38. doi: 10.1097/SLA.0b013e31818b7595
5. Clinical Outcomes of Surgical Therapy Study G, Nelson H, Sargent DJ, et al. A comparison of laparoscopically assisted and open colectomy for colon cancer. *N Engl J Med* 2004;350(20):2050-9. doi: 10.1056/NEJMoa032651 [published Online First: 2004/05/14]
6. Veldkamp R, Kuhry E, Hop WC, et al. Laparoscopic surgery versus open surgery for colon cancer: short-term outcomes of a randomised trial. *Lancet Oncol* 2005;6(7):477-84. doi: 10.1016/S1470-2045(05)70221-7 [published Online First: 2005/07/05]
7. Guillou PJ, Quirke P, Thorpe H, et al. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. *The Lancet* 2005;365(9472):1718-26. doi: 10.1016/s0140-6736(05)66545-2
8. Stucky CC, Pockaj BA, Novotny PJ, et al. Long-term follow-up and individual item analysis of quality of life assessments related to laparoscopic-assisted colectomy in the COST trial 93-46-53 (INT 0146). *Ann Surg Oncol* 2011;18(9):2422-31. doi: 10.1245/s10434-011-1650-2 [published Online First: 2011/04/01]
9. Jayne DG, Thorpe HC, Copeland J, et al. Five-year follow-up of the Medical Research Council CLASICC trial of laparoscopically assisted versus open surgery for colorectal cancer. *Br J Surg* 2010;97(11):1638-45. doi: 10.1002/bjs.7160 [published Online First: 2010/07/16]
10. Colon Cancer Laparoscopic or Open Resection Study G, Buunen M, Veldkamp R, et al. Survival after laparoscopic surgery versus open surgery for colon cancer: long-term outcome of a randomised clinical trial. *Lancet Oncol* 2009;10(1):44-52. doi: 10.1016/S1470-2045(08)70310-3 [published Online First: 2008/12/17]
11. Bagshaw PF, Allardyce RA, Frampton CM, et al. Long-term outcomes of the australasian randomized clinical trial comparing laparoscopic and conventional open surgical treatments for colon cancer: the Australasian Laparoscopic Colon Cancer Study trial. *Ann Surg* 2012;256(6):915-9. doi: 10.1097/SLA.0b013e3182765ff8 [published Online First: 2012/11/17]
12. Schwenk W, Haase O, Neudecker J, et al. Short term benefits for laparoscopic colorectal resection. *Cochrane Database Syst Rev* 2005(3):CD003145. doi: 10.1002/14651858.CD003145.pub2 [published Online First: 2005/07/22]
13. Kuhry E, Schwenk WF, Gaupset R, et al. Long-term results of laparoscopic colorectal cancer resection. *Cochrane Database Syst Rev* 2008(2):CD003432. doi: 10.1002/14651858.CD003432.pub2 [published Online First: 2008/04/22]
14. Lacy AM, Delgado S, Castells A, et al. The long-term results of a randomized clinical trial of laparoscopy-assisted versus open surgery for colon cancer. *Ann Surg* 2008;248(1):1-7. doi: 10.1097/SLA.0b013e31816a9d65 [published Online First: 2008/06/27]
15. Meguid RA, Slidell MB, Wolfgang CL, et al. Is there a difference in survival between right- versus left-sided colon cancers? *Ann Surg Oncol* 2008;15(9):2388-94. doi: 10.1245/s10434-008-0015-y [published Online First: 2008/07/16]

16. Gervaz P, Bucher P, Morel P. Two colons-two cancers: paradigm shift and clinical implications. *J Surg Oncol* 2004;88(4):261-6. doi: 10.1002/jso.20156 [published Online First: 2004/11/27]
17. Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. *Ann Intern Med* 1990;113(10):779-88. doi: 10.7326/0003-4819-113-10-779 [published Online First: 1990/11/15]
18. Benedix F, Kube R, Meyer F, et al. Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. *Dis Colon Rectum* 2010;53(1):57-64. doi: 10.1007/DCR.0b013e3181c703a4 [published Online First: 2009/12/17]
19. Desiderio J, Trastulli S, Ricci F, et al. Laparoscopic versus open left colectomy in patients with sigmoid colon cancer: prospective cohort study with long-term follow-up. *Int J Surg* 2014;12(8):745-50. doi: 10.1016/j.ijso.2014.05.074 [published Online First: 2014/06/03]
20. Hsu YJ, Chern YJ, Jhuang JR, et al. Efficient and Safe Method for Splenic Flexure Mobilization in Laparoscopic Left Hemicolectomy: A Propensity Score-weighted Cohort Study. *Surg Laparosc Endosc Percutan Tech* 2020;31(2):196-202. doi: 10.1097/SLE.0000000000000884 [published Online First: 2020/12/08]
21. Braga M, Frasson M, Zuliani W, et al. Randomized clinical trial of laparoscopic versus open left colonic resection. *Br J Surg* 2010;97(8):1180-6. doi: 10.1002/bjs.7094 [published Online First: 2010/07/06]
22. Liang JT, Huang KC, Lai HS, et al. Oncologic results of laparoscopic versus conventional open surgery for stage II or III left-sided colon cancers: a randomized controlled trial. *Ann Surg Oncol* 2007;14(1):109-17. doi: 10.1245/s10434-006-9135-4 [published Online First: 2006/10/27]
23. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4:1. doi: 10.1186/2046-4053-4-1 [published Online First: 2015/01/03]
24. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ* 2015;350:g7647. doi: 10.1136/bmj.g7647 [published Online First: 2015/01/04]
25. Booth A, Clarke M, Dooley G, et al. The nuts and bolts of PROSPERO: an international prospective register of systematic reviews. *Syst Rev* 2012;1:2. doi: 10.1186/2046-4053-1-2 [published Online First: 2012/05/17]
26. Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. *Statistics in Medicine* 1998;17(24):2815-34. doi: 10.1002/(sici)1097-0258(19981230)17:24<2815::Aid-sim110>3.0.Co;2-8
27. Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. *Trials* 2007;8:16. doi: 10.1186/1745-6215-8-16 [published Online First: 2007/06/09]
28. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ* 2003;327(7414):557-60. doi: 10.1136/bmj.327.7414.557 [published Online First: 2003/09/06]
29. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011;343:d5928. doi: 10.1136/bmj.d5928 [published Online First: 2011/10/20]
30. GA Wells, B Shea, D O'Connell, et al. The Newcastle-Ottawa Scale (NOS) for assessing the

1
2
3 quality of nonrandomised studies in meta-analyses [Available from:
4 http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp accessed February 11 2022.

- 5
6 31. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of
7 evidence and strength of recommendations. *BMJ* 2008;336(7650):924-6. doi:
8 10.1136/bmj.39489.470347.AD [published Online First: 2008/04/26]
9
10 32. Jacobs M, Verdeja JC, HS G. Minimally invasive colon resection (laparoscopic colectomy). *Surg*
11 *Laparosc Endosc* 1991;1(3):144-50.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Reporting checklist for protocol of a systematic review and meta analysis.

Based on the PRISMA-P guidelines.

			Page Number
Title			
Identification	#1a	Identify the report as a protocol of a systematic review	1
Update	#1b	If the protocol is for an update of a previous systematic review, identify as such	n/a
Registration			
	#2	If registered, provide the name of the registry (such as PROSPERO) and registration number	2
Authors			
Contact	#3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contribution	#3b	Describe contributions of protocol authors and identify the guarantor of the review	10
Amendments			
	#4	If the protocol represents an amendment of a previously	n/a

completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments

Support

11	Sources	#5a	Indicate sources of financial or other support for the review	10
14	Sponsor	#5b	Provide name for the review funder and / or sponsor	10
17	Role of sponsor or funder	#5c	Describe roles of funder(s), sponsor(s), and / or institution(s), if any, in developing the protocol	10

Introduction

26	Rationale	#6	Describe the rationale for the review in the context of what is already known	3
31	Objectives	#7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	4, 5

Methods

42	Eligibility criteria	#8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	4, 5
52	Information sources	#9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	5

1	Search strategy	#10	Present draft of search strategy to be used for at least one	6
2			electronic database, including planned limits, such that it	
3			could be repeated	
4				
5				
6				
7				
8	Study records -	#11a	Describe the mechanism(s) that will be used to manage	6
9	data management		records and data throughout the review	
10				
11				
12				
13	Study records -	#11b	State the process that will be used for selecting studies (such	6
14	selection process		as two independent reviewers) through each phase of the	
15			review (that is, screening, eligibility and inclusion in meta-	
16			analysis)	
17				
18				
19				
20				
21				
22				
23	Study records -	#11c	Describe planned method of extracting data from reports	7
24	data collection		(such as piloting forms, done independently, in duplicate),	
25	process		any processes for obtaining and confirming data from	
26			investigators	
27				
28				
29				
30				
31				
32				
33	Data items	#12	List and define all variables for which data will be sought	7
34			(such as PICO items, funding sources), any pre-planned data	
35			assumptions and simplifications	
36				
37				
38				
39				
40				
41	Outcomes and	#13	List and define all outcomes for which data will be sought,	5
42	prioritization		including prioritization of main and additional outcomes, with	
43			rationale	
44				
45				
46				
47				
48				
49	Risk of bias in	#14	Describe anticipated methods for assessing risk of bias of	8
50	individual studies		individual studies, including whether this will be done at the	
51			outcome or study level, or both; state how this information will	
52			be used in data synthesis	
53				
54				
55				
56				
57				
58				
59				
60				

1	Data synthesis	#15a	Describe criteria under which study data will be quantitatively	7, 8
2			synthesised	
3				
4				
5				
6	Data synthesis	#15b	If data are appropriate for quantitative synthesis, describe	8
7			planned summary measures, methods of handling data and	
8			methods of combining data from studies, including any	
9			planned exploration of consistency (such as I ² , Kendall's τ)	
10				
11				
12				
13				
14				
15				
16	Data synthesis	#15c	Describe any proposed additional analyses (such as	8
17			sensitivity or subgroup analyses, meta-regression)	
18				
19				
20				
21				
22	Data synthesis	#15d	If quantitative synthesis is not appropriate, describe the type	8
23			of summary planned	
24				
25				
26				
27	Meta-bias(es)	#16	Specify any planned assessment of meta-bias(es) (such as	8
28			publication bias across studies, selective reporting within	
29			studies)	
30				
31				
32				
33				
34				
35	Confidence in	#17	Describe how the strength of the body of evidence will be	9
36	cumulative		assessed (such as GRADE)	
37	evidence			
38				
39				
40				
41				

The PRISMA-P elaboration and explanation paper is distributed under the terms of the Creative Commons Attribution License CC-BY. This checklist was completed on 18. February 2022 using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

BMJ Open

Laparoscopic versus open left hemicolectomy for left-sided colon cancer: protocol for a systematic review and meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-062216.R1
Article Type:	Protocol
Date Submitted by the Author:	01-May-2022
Complete List of Authors:	Du, Qiang; Sichuan University West China Hospital, Department of Gastrointestinal Surgery Yang, Yang; Sichuan University West China Hospital, Department of Gastrointestinal Surgery Zhang, Jianhao; Sichuan University West China Hospital, Department of Gastrointestinal Surgery Liu, Xueting; Sichuan University West China Hospital, Department of Evidence-Based Medicine and Clinical Epidemiology Wang, Yong; Sichuan University West China Hospital, Department of Gastrointestinal Surgery Yang, Lie; Sichuan University West China Hospital, Department of Gastrointestinal Surgery; Sichuan University West China Hospital, Institute of Digestive Surgery, State Key Laboratory of Biotherapy and Cancer Center
Primary Subject Heading:	Gastroenterology and hepatology
Secondary Subject Heading:	Gastroenterology and hepatology, Surgery
Keywords:	Colorectal surgery < SURGERY, Gastrointestinal tumours < ONCOLOGY, SURGERY

SCHOLARONE™
Manuscripts

1
2
3
4
5
6 **Laparoscopic versus open left hemicolectomy for left-sided colon**
7
8
9 **cancer: protocol for a systematic review and meta-analysis**
10

11
12 Qiang Du^{#1}, Yang Yang^{#1}, Jianhao Zhang¹, Xueting Liu², Yong Wang^{1*}, Lie Yang^{1,3*}
13

14 ¹Department of Gastrointestinal Surgery, West China Hospital of Sichuan University, No. 37
15 Guoxue Lane, Chengdu, 610041, Sichuan Province, China.
16

17
18
19 ²Department of Evidence-Based Medicine and Clinical Epidemiology, West China Hospital of
20 Sichuan University, No. 37 Guoxue Lane, Chengdu, 610041, Sichuan Province, China.
21

22
23
24 ³Institute of Digestive Surgery, State Key Laboratory of Biotherapy and Cancer Center, West
25 China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.
26

27
28 **#Contributed equally to this manuscript.**
29

30
31 ***Corresponding author:**
32

33 Lie Yang, Department of Gastrointestinal Surgery, West China Hospital of Sichuan University,
34 No. 37 Guoxue Lane, Chengdu, 610041, China; Institute of Digestive Surgery, State Key
35 Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu,
36 610041, Sichuan, China; Tel: +86 28 85164035; Fax: +86 28 85164035; E-mail:
37
38
39 lie_222@163.com.
40
41
42

43
44 Yong Wang, Department of Gastrointestinal Surgery, West China Hospital of Sichuan University,
45 No. 37 Guoxue Lane, Chengdu, 610041, China. E-mail :wydoctor1974@aliyun.com.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction: Laparoscopic colectomy has been widely used clinically due to its minimally invasive advantages, and many studies have also demonstrated its safety and efficacy. However, the efficacy of laparoscopic left hemicolectomy remains unclear due to the differences in pathogenesis and surgical details between left and right colon cancers. Therefore, we plan to conduct a systematic review and meta-analysis to investigate whether laparoscopic techniques can be safely used in left hemicolectomy.

Method and analysis: This meta-analysis protocol will be completed and reported according to PRISMA-P (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols) guidelines. A systematic search was performed for all articles related to laparoscopic left hemicolectomy in PubMed, Web of Science, Medline, EMBASE, and the Cochrane Library from inception to November 5, 2021. Article screening and data extraction were performed independently by two authors and cross-checked after completion. The literature to be included will use corresponding tools for bias risk assessment. Subgroup analyses and sensitivity analyses will be used to explore potential heterogeneity.

Ethics and dissemination: Because this systematic review is based on studies with published results and does not involve intervention in patients, no ethical review is required. The results of this study will be published in a peer-reviewed journal.

PROSPERO registration number: CRD42022291526.

Strength and limitations of this study:

To the best of our knowledge, this will be the first meta-analysis to compare surgical approaches for left hemicolectomy.

Subgroup and sensitivity analyses will be used to explore potential heterogeneity.

Both the quality of the included literature and the final outcomes will be evaluated.

Restriction of publication language to English only is a limitation of this study.

INTRODUCTION

Colorectal cancer (CRC) is the third most commonly diagnosed malignant tumor and the third leading cause of tumor-related deaths worldwide. [1](#) [2](#) At present, surgery is still the main treatment for CRC, and laparoscopic surgery has become widely accepted due to its minimally invasive advantages. Although laparoscopic rectal cancer surgery remains controversial, laparoscopic colon cancer surgery has been recommended early by the National Comprehensive Cancer Network (NCCN) guidelines,[3](#) mainly based on several large multicenter RCTs, including the Australasian Laparoscopic Colon Cancer Study (ALCCaS) Trial,[4](#) the Clinical Outcomes of Surgical Therapy (COST) study,[5](#) the Medical Research Council Conventional versus Laparoscopic-Assisted Surgery In Colorectal Cancer (MRC CLASICC) trial and the Colon Cancer Laparoscopic or Open Resection (COLOR) Study.[6](#) [7](#) These trials have demonstrated that laparoscopic colectomy is superior to conventional open surgery in terms of short-term outcomes, such as surgical incision length, intraoperative bleeding, and postoperative functional recovery, while also demonstrating that the adequacy of tumor removal is not threatened and that tumor-related long-term outcomes are not significantly different from those of open surgery.[8-11](#) In addition, these results have also been verified by the Cochrane Database of Systematic Reviews.[12](#) [13](#)

However, left-sided colon cancer has been underrepresented in these trials, as the patients who underwent left hemicolectomy accounted for a very low proportion in the included cases, such as 113 (10.4%) in the COLOR study,[10](#) 59 (7.4%) and 64 (7.4%) in the CLASICC trial and COST study,[5](#) [7](#) respectively, and even fewer in the ALCCaS and Barcelona trials, with only 22 (3.7%) and 5 (2.3%),[11](#) [14](#) respectively. Compared to right hemicolectomy or transverse colectomy, left hemicolectomy has quite different anatomic features and surgical procedures, with a challenge in the mobilization of splenic flexure. Furthermore, it has been widely accepted that right and left colon cancers are two different diseases based on their differences in embryonic origin, genetic characteristics, and biological behaviors and therefore may have different survival outcomes.[15-18](#) Therefore, the safety and prognosis of the treatment of left and right colon cancer should be evaluated separately by site, but the existing clinical trials are not representative of left hemicolectomy, so there is an urgent need to study this topic.

1
2
3
4 At present, several clinical trials have been conducted specifically on laparoscopic left
5 hemicolecotomy,[19 20](#) and even results from RCTs have been published,[21 22](#) but these results
6 lack a pooling to form evidence-based medical evidence. Therefore, the purpose of this study
7 was to synthesize the published results to fill the evidence gap for laparoscopic techniques for
8 left hemicolecotomy and to remind future investigators conducting colon cancer-related studies
9 to stratify the final results based on the different locations of the tumor if there are
10 inconsistencies between the results of this study and those of the whole colon.
11
12
13
14
15
16

17 18 **MATERIALS AND METHODS**

19
20
21 This meta-analysis protocol will be completed and reported according to PRISMA-P (Preferred
22 Reporting Items for Systematic Reviews and Meta-Analyses Protocols) guidelines.[23 24](#)
23 According to the guidelines, our study has been registered on the website of the International
24 Prospective Register of Systematic Reviews (PROSPERO).[25](#) The registration number is
25 CRD42022291526.
26
27
28
29
30
31

32 **Inclusion criteria:**

33
34
35 Population: All patients with left-sided colon cancer confirmed by preoperative imaging and
36 pathology who underwent left hemicolecotomy with mobilization of splenic flexure were the
37 target population of our study.
38
39
40

41
42 Intervention: The intervention in the experimental group was laparoscopic left hemicolecotomy.
43 In this meta-analysis, the definition of left hemicolecotomy mainly included four aspects. First,
44 ligation of the corresponding vessels, such as the inferior mesenteric vein (IMV), was
45 performed. Second, mobilization and pull-down of splenic flexure were observed. Third,
46 resection of the distal transverse colon, splenic flexure, descending colon, sigmoid, etc. Finally,
47 either an intracorporeal anastomosis or an extracorporeal anastomosis is performed for
48 colocolonic anastomosis or colorectal anastomosis. Slight adjustments during the procedure to
49 suit the actual situation are considered acceptable.
50
51
52
53
54
55
56

57
58 Comparison: Traditional open left hemicolecotomy.
59
60

1
2
3
4 Outcome: The outcomes assessed in this systematic review and meta-analysis included
5 perioperative outcomes (operative time, estimated blood loss, length of incision, time to resume
6 oral diet, time to peristalsis), postoperative outcomes (length of hospital stay, number of
7 harvested lymph nodes, 30-day mortality, postoperative complications), and oncological
8 outcomes (tumor recurrence, 5-year overall survival, and 5-year disease-free survival). In this
9 study, oncologic outcomes were considered primary outcomes, with perioperative and
10 postoperative outcomes as secondary outcomes. In this study, tumor recurrence was defined as
11 any recurrence confirmed by imaging or pathology, including local recurrence and systemic
12 recurrence. DFS was defined as the duration from the date of surgery to confirmed recurrence
13 or death from any cause, and OS was defined as the duration from the date of surgery to the
14 date of proven death from any cause.
15
16
17
18
19
20
21
22
23
24

25 Study design: All randomized controlled and nonrandomized controlled clinical studies
26 comparing laparoscopic left hemicolectomy with open left hemicolectomy for which full text
27 was available were included.
28
29
30
31

32 **Exclusion criteria:**

- 33 1. Studies that included tumors from other colorectal locations but did not analyse the left
34 hemicolectomy separately or for which data from the left hemicolectomy were not extractable
35 were not included.
 - 36 2. Benign colorectal disease or emergency surgery will be excluded.
 - 37 3. No splenic flexure mobilization will also be excluded.
 - 38 4. Noncomparative studies and non-English publications were excluded.
- 39
40
41
42
43
44
45
46
47

48 **Study Selection**

49
50
51 We systematically searched the PubMed, Web of Science, Medline, EMBASE, and Cochrane
52 Library databases for all literature comparing laparoscopic and open surgical approaches for
53 left hemicolectomy from inception to November 5, 2021. Searches were carried out using
54 medical subject headings (MeSH) and free text words in combination with the search strategy.
55 We used the following keywords: “colon cancer”, “left hemicolectomy”, “laparoscopy” and
56
57
58
59
60

“open”. All possible forms of these keywords will be used to ensure the comprehensiveness of the search. Additionally, we enriched our retrieval results with several methods, such as the similar articles function in PubMed, cross-checking references of the retrieved literature, searching ClinicalTrials (<https://www.clinicaltrials.gov/>), etc.

Search Terms for PubMed

#1 (((((((((((((((((((Colonic Neoplasms) OR (Neoplasm, Colonic)) OR (Neoplasms, Colonic)) OR (Colon Neoplasms)) OR (Colon Neoplasm)) OR (Neoplasm, Colon)) OR (Neoplasms, Colon)) OR (Cancer of Colon)) OR (Colon Cancers)) OR (Colon Cancer)) OR (Cancer, Colon)) OR (Cancers, Colon)) OR (Cancer of the Colon)) OR (Colonic Cancer)) OR (Cancer, Colonic)) OR (Cancers, Colonic)) OR (Colonic Cancers)) OR (Colon Adenocarcinoma)) OR (Adenocarcinoma, Colon)) OR (Adenocarcinomas, Colon)) OR (Colon Adenocarcinomas)

#2 open surgery

#3 (((((((((((((((((((Laparoscopy) OR (Celioscopy)) OR (Peritoneoscopy)) OR (Surgical Procedures, Laparoscopic)) OR (Laparoscopic Surgical Procedure)) OR (Procedure, Laparoscopic Surgical)) OR (Procedures, Laparoscopic Surgical)) OR (Surgery, Laparoscopic)) OR (Laparoscopic Surgical Procedures)) OR (Laparoscopic Surgery)) OR (Laparoscopic Surgeries)) OR (Surgeries, Laparoscopic)) OR (Laparoscopic Assisted Surgery)) OR (Laparoscopic Assisted Surgeries)) OR (Surgeries, Laparoscopic Assisted)) OR (Surgery, Laparoscopic Assisted)) OR (Surgical Procedure, Laparoscopic)

#4 (left hemicolectomy) OR (left colectomy)

#5 #2 AND #3

#6 #1 AND #4 AND #5

The management of the literature search records will be carried out in EndNote X9.1. Two authors (QD and JZ) independently performed an initial screening of the titles and abstracts of the search results and assessed the eligibility of the articles. After removing duplicates and irrelevant literature, the two authors will assess the eligibility of the articles according to the inclusion criteria after reading the full text of the remaining articles separately. Any controversial points arising during this process will be referred to a third author (LY) and

1
2
3
4 discussed until the dispute is resolved. The specific literature screening process will be
5 summarized in a flow diagram.
6
7

8 **Data Extraction**

9
10
11 Data to be collected, such as study details (first author, year of publication, study design, follow-
12 up period, type of outcome), patient demographics (age, sex, American Society of
13 Anesthesiologists (ASA) score, tumor stage, etc.), and the outcomes of interest mentioned
14 above will be consolidated into a piloting spreadsheet. Additionally, we will extract the effect
15 estimates of the outcome of interest for statistical analysis. If there were multiple
16 representations of the data, we preferred to use the data after adjusting for confounding factors.
17
18 To reduce bias and reduce errors in data extraction, the same two investigators (QD and JZ)
19 independently extracted data from the included literature, cross-checked after extraction, and
20 disagreements were resolved by discussion and, if necessary, by asking a third author (LY) to
21 resolve. Because this analysis was based on the intention-to-treat principle, all patients who
22 were converted from the laparoscopic group to the conventional open surgery group remained
23 in the laparoscopic group for analysis. We will also use sensitivity analyses to assess the impact
24 of including studies that do not report intention-to-treat on overall outcomes.
25
26

27
28 There are currently several RCTs, such as COST, CLASICC, ALCCaS, and COLOR,
29 comparing laparoscopic and open colectomy, and we believe that inclusion of their data would
30 enhance the quality of our evidence for this study. We will be sending emails to the authors of
31 these trials asking for stratified data on left hemicolectomy. Meanwhile, for the missing data
32 of other studies, we will also send an email to ask for.
33
34
35
36
37

38 **Statistical Analysis**

39
40 Statistically, it is not possible to combine the median with the mean value, and only data
41 expressed as the mean and standard deviation can be used for meta-analysis. In this study, we
42 will not use the median to estimate the mean, as other studies have done, because we believe
43 this would not be worth the cost. The weighted mean difference (WMD) or standardized mean
44 difference (SMD) and corresponding 95% confidence interval (CI) were used for the analysis
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 of continuous variables. The dichotomous variables were analysed using risk ratio (RR) values
5 with 95% CIs. Considering the characteristics of survival analysis, we will first attempt to
6 extract survival analysis-related data from the included studies and then calculate the pooled
7 hazard ratio (HR). HR and 95% CI will be extracted directly from the article, and if not reported
8 in the article, we consider using software such as Engauge Digitizer to obtain the required data
9 from Kaplan–Meier curves following the method provided by Parmar et al.[26](#) Finally, the
10 obtained data will be integrated into the spreadsheet designed by Tierney et al. to calculate the
11 HR and 95% CI.[27](#) If the data were insufficient or the HR was not available for other reasons,
12 then the pooled OR values of OS and DFS were calculated separately.

13
14
15
16
17
18
19
20
21
22 Statistical heterogeneity among the studies was calculated by the chi-squared (χ^2) test and I-
23 squared (I^2) test.[28](#) We considered that high heterogeneity existed if the value of $P < 0.1$ or $I^2 >$
24 50%. When the heterogeneity was 0, the fixed-effects model was used, and when the
25 heterogeneity was between 0-50%, the random-effects model was used. We will conduct
26 subgroup analyses, based on different study design types, and meta-regression so that we can
27 explore the potential causes of heterogeneity and reduce it as accurately as possible when
28 heterogeneity exceeded 50%. If the heterogeneity is too high, then qualitative analysis was
29 performed. Sensitivity analysis will be performed to determine the robustness of the results by
30 sequentially excluding one study at a time. $P < 0.05$ was considered statistically significant.
31 Software such as RevMan 5.4 and STATA 16 will be used for statistical processing. Publication
32 bias will be estimated by visual assessment of funnel plots if ≥ 10 studies are available. If the
33 extracted data are not suitable for pooling, a systematic narrative synthesis will be presented in
34 textual form.

45 46 47 48 **Risk Of Bias Assessment**

49
50
51
52 Quality assessment will be carried out by two authors (QD and JZ), and discrepancies will be
53 resolved through discussion. If consensus was not reached, then the third author (LY) was
54 consulted for arbitration. The risk of bias in randomized controlled trials will be assessed using
55 the Cochrane Risk of Bias Tool,[29](#) which includes six aspects: randomization, allocation
56 concealment, application of blinding, integrity of outcome data, selective reporting, and other
57
58
59
60

1
2
3
4 biases. For each, we will use high risk, low risk, or unclear risk to assess the results. The
5
6 methodological quality of nonrandomized controlled trials will be evaluated using the
7
8 Newcastle–Ottawa Scale (NOS),³⁰ which consists of three aspects: patient selection,
9
10 comparability of cohorts, and assessment of outcome. The total score is 9 stars, and each article
11
12 is classified as low quality (0-5 stars) or high quality (6-9 stars). The final results will be
13
14 summarized in a table.

15 16 17 **Evidence Quality Evaluation**

18
19
20 The quality of evidence for each outcome will be evaluated using the Grading of
21
22 Recommendations Assessment, Development and Evaluation (GRADE) system,³¹ with four
23
24 levels: high, moderate, low, and very low.

25 26 27 **Patient And Public Involvement**

28
29
30 Since this study is a secondary study based on other studies, there will be no direct patient or
31
32 public involvement in this study.

33 34 35 **Ethics And Dissemination**

36
37
38 Because no patients were involved, ethical approval was not required. The final results of this
39
40 research will be submitted to a peer-reviewed journal or presented at relevant conferences, and
41
42 any deviations from this protocol will be recorded and explained in the final report.

43
44
45
46
47 **Contributors:** The original idea was conceived by LY. QD and YY drafted the manuscript for
48
49 this protocol. QD, YY, JHZ, YW, LY participated in the design of the study and the setting of the
50
51 inclusion and exclusion criteria. QD and YY design the search strategy, and XTL will be
52
53 responsible for the modifications. QD and JHZ will perform the literature screening and data
54
55 extraction. YW and LY will review the overall work. All authors have read and approved the
56
57 publication of the protocol.

58
59
60 **Funding:** This work was supported by Wu Jieping Medical Foundation (No.312180452).

1
2
3
4 **Competing interests:** None declared.
5

6 **Ethical approval:** Not required.
7

8
9 **Patient consent for publication:** Not required.
10

11 **Provenance and peer review:** Not commissioned; externally peer reviewed.
12

13
14 **Open access:** This is an open access article distributed in accordance with the Creative Commons
15 Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix,
16 adapt, build upon this work non-commercially, and license their derivative works on different
17 terms, provided the original work is properly cited, appropriate credit is given, any changes made
18 indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.
19
20
21
22

23 **ORCID iDs**

24
25
26
27 Qiang Du: <https://orcid.org/0000-0002-7283-1140>
28

29
30 Lie Yang: <https://orcid.org/0000-0003-1178-7147>
31

32 **Word count** 2102
33

34 **REFERENCES**

- 35
36
37
38 1. Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021. *CA Cancer J Clin* 2021;71(1):7-33.
39 doi: 10.3322/caac.21654 [published Online First: 2021/01/13]
40
41 2. Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020. *CA Cancer J Clin*
42 2020;70(3):145-64. doi: 10.3322/caac.21601 [published Online First: 2020/03/07]
43
44 3. Benson AB, Venook AP, Al-Hawary MM, et al. Colon Cancer, Version 2.2021, NCCN Clinical
45 Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2021;19(3):329-59. doi:
46 10.6004/jnccn.2021.0012 [published Online First: 2021/03/17]
47
48 4. Hewett PJ, Allardyce RA, Bagshaw PF, et al. Short-Term Outcomes of the Australasian Randomized
49 Clinical Study Comparing Laparoscopic and Conventional Open Surgical Treatments for Colon
50 Cancer. *Annals of Surgery* 2008;248(5):728-38. doi: 10.1097/SLA.0b013e31818b7595
51
52 5. Clinical Outcomes of Surgical Therapy Study G, Nelson H, Sargent DJ, et al. A comparison of
53 laparoscopically assisted and open colectomy for colon cancer. *N Engl J Med*
54 2004;350(20):2050-9. doi: 10.1056/NEJMoa032651 [published Online First: 2004/05/14]
55
56 6. Veldkamp R, Kuhry E, Hop WC, et al. Laparoscopic surgery versus open surgery for colon cancer:
57 short-term outcomes of a randomised trial. *Lancet Oncol* 2005;6(7):477-84. doi:
58 10.1016/S1470-2045(05)70221-7 [published Online First: 2005/07/05]
59
60 7. Guillou PJ, Quirke P, Thorpe H, et al. Short-term endpoints of conventional versus laparoscopic-

- 1
2
3 assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre,
4 randomised controlled trial. *The Lancet* 2005;365(9472):1718-26. doi: 10.1016/s0140-
5 6736(05)66545-2
6
7
8 8. Stucky CC, Pockaj BA, Novotny PJ, et al. Long-term follow-up and individual item analysis of quality
9 of life assessments related to laparoscopic-assisted colectomy in the COST trial 93-46-53 (INT
10 0146). *Ann Surg Oncol* 2011;18(9):2422-31. doi: 10.1245/s10434-011-1650-2 [published
11 Online First: 2011/04/01]
12
13 9. Jayne DG, Thorpe HC, Copeland J, et al. Five-year follow-up of the Medical Research Council
14 CLASICC trial of laparoscopically assisted versus open surgery for colorectal cancer. *Br J Surg*
15 2010;97(11):1638-45. doi: 10.1002/bjs.7160 [published Online First: 2010/07/16]
16
17 10. Colon Cancer Laparoscopic or Open Resection Study G, Buunen M, Veldkamp R, et al. Survival
18 after laparoscopic surgery versus open surgery for colon cancer: long-term outcome of a
19 randomised clinical trial. *Lancet Oncol* 2009;10(1):44-52. doi: 10.1016/S1470-2045(08)70310-
20 3 [published Online First: 2008/12/17]
21
22 11. Bagshaw PF, Allardyce RA, Frampton CM, et al. Long-term outcomes of the australasian randomized
23 clinical trial comparing laparoscopic and conventional open surgical treatments for colon cancer:
24 the Australasian Laparoscopic Colon Cancer Study trial. *Ann Surg* 2012;256(6):915-9. doi:
25 10.1097/SLA.0b013e3182765ff8 [published Online First: 2012/11/17]
26
27 12. Schwenk W, Haase O, Neudecker J, et al. Short term benefits for laparoscopic colorectal resection.
28 *Cochrane Database Syst Rev* 2005(3):CD003145. doi: 10.1002/14651858.CD003145.pub2
29 [published Online First: 2005/07/22]
30
31 13. Kuhry E, Schwenk WF, Gaupset R, et al. Long-term results of laparoscopic colorectal cancer
32 resection. *Cochrane Database Syst Rev* 2008(2):CD003432. doi:
33 10.1002/14651858.CD003432.pub2 [published Online First: 2008/04/22]
34
35 14. Lacy AM, Delgado S, Castells A, et al. The long-term results of a randomized clinical trial of
36 laparoscopy-assisted versus open surgery for colon cancer. *Ann Surg* 2008;248(1):1-7. doi:
37 10.1097/SLA.0b013e31816a9d65 [published Online First: 2008/06/27]
38
39 15. Meguid RA, Slidell MB, Wolfgang CL, et al. Is there a difference in survival between right- versus
40 left-sided colon cancers? *Ann Surg Oncol* 2008;15(9):2388-94. doi: 10.1245/s10434-008-0015-
41 y [published Online First: 2008/07/16]
42
43 16. Gervaz P, Bucher P, Morel P. Two colons-two cancers: paradigm shift and clinical implications. *J*
44 *Surg Oncol* 2004;88(4):261-6. doi: 10.1002/jso.20156 [published Online First: 2004/11/27]
45
46 17. Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal
47 tumor location. *Ann Intern Med* 1990;113(10):779-88. doi: 10.7326/0003-4819-113-10-779
48 [published Online First: 1990/11/15]
49
50 18. Benedix F, Kube R, Meyer F, et al. Comparison of 17,641 patients with right- and left-sided colon
51 cancer: differences in epidemiology, perioperative course, histology, and survival. *Dis Colon*
52 *Rectum* 2010;53(1):57-64. doi: 10.1007/DCR.0b013e3181c703a4 [published Online First:
53 2009/12/17]
54
55 19. Desiderio J, Trastulli S, Ricci F, et al. Laparoscopic versus open left colectomy in patients with
56 sigmoid colon cancer: prospective cohort study with long-term follow-up. *Int J Surg*
57 2014;12(8):745-50. doi: 10.1016/j.ijso.2014.05.074 [published Online First: 2014/06/03]
58
59 20. Hsu YJ, Chern YJ, Jhuang JR, et al. Efficient and Safe Method for Splenic Flexure Mobilization in
60 Laparoscopic Left Hemicolectomy: A Propensity Score-weighted Cohort Study. *Surg Laparosc*

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Endosc Percutan Tech* 2020;31(2):196-202. doi: 10.1097/SLE.0000000000000884 [published Online First: 2020/12/08]
21. Braga M, Frasson M, Zuliani W, et al. Randomized clinical trial of laparoscopic versus open left colonic resection. *Br J Surg* 2010;97(8):1180-6. doi: 10.1002/bjs.7094 [published Online First: 2010/07/06]
22. Liang JT, Huang KC, Lai HS, et al. Oncologic results of laparoscopic versus conventional open surgery for stage II or III left-sided colon cancers: a randomized controlled trial. *Ann Surg Oncol* 2007;14(1):109-17. doi: 10.1245/s10434-006-9135-4 [published Online First: 2006/10/27]
23. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4:1. doi: 10.1186/2046-4053-4-1 [published Online First: 2015/01/03]
24. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ* 2015;350:g7647. doi: 10.1136/bmj.g7647 [published Online First: 2015/01/04]
25. Booth A, Clarke M, Dooley G, et al. The nuts and bolts of PROSPERO: an international prospective register of systematic reviews. *Syst Rev* 2012;1:2. doi: 10.1186/2046-4053-1-2 [published Online First: 2012/05/17]
26. Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. *Statistics in Medicine* 1998;17(24):2815-34. doi: 10.1002/(sici)1097-0258(19981230)17:24<2815::Aid-sim110>3.0.Co;2-8
27. Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. *Trials* 2007;8:16. doi: 10.1186/1745-6215-8-16 [published Online First: 2007/06/09]
28. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ* 2003;327(7414):557-60. doi: 10.1136/bmj.327.7414.557 [published Online First: 2003/09/06]
29. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011;343:d5928. doi: 10.1136/bmj.d5928 [published Online First: 2011/10/20]
30. GA Wells, B Shea, D O'Connell, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp accessed February 11 2022.
31. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;336(7650):924-6. doi: 10.1136/bmj.39489.470347.AD [published Online First: 2008/04/26]

Reporting checklist for protocol of a systematic review and meta analysis.

Based on the PRISMA-P guidelines.

			Page Number
Title			
Identification	#1a	Identify the report as a protocol of a systematic review	1
Update	#1b	If the protocol is for an update of a previous systematic review, identify as such	n/a
Registration			
	#2	If registered, provide the name of the registry (such as PROSPERO) and registration number	2
Authors			
Contact	#3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contribution	#3b	Describe contributions of protocol authors and identify the guarantor of the review	10
Amendments			
	#4	If the protocol represents an amendment of a previously	n/a

completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments

Support

11	Sources	#5a	Indicate sources of financial or other support for the review	10
14	Sponsor	#5b	Provide name for the review funder and / or sponsor	10
17	Role of sponsor or funder	#5c	Describe roles of funder(s), sponsor(s), and / or institution(s), if any, in developing the protocol	10

Introduction

26	Rationale	#6	Describe the rationale for the review in the context of what is already known	3
31	Objectives	#7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	4, 5

Methods

42	Eligibility criteria	#8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	4, 5
52	Information sources	#9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	5

1	Search strategy	#10	Present draft of search strategy to be used for at least one	6
2			electronic database, including planned limits, such that it	
3			could be repeated	
4				
5				
6				
7				
8	Study records -	#11a	Describe the mechanism(s) that will be used to manage	6
9			records and data throughout the review	
10	data management			
11				
12				
13				
14	Study records -	#11b	State the process that will be used for selecting studies (such	6
15			as two independent reviewers) through each phase of the	
16	selection process		review (that is, screening, eligibility and inclusion in meta-	
17			analysis)	
18				
19				
20				
21				
22				
23				
24	Study records -	#11c	Describe planned method of extracting data from reports	7
25			(such as piloting forms, done independently, in duplicate),	
26	data collection		any processes for obtaining and confirming data from	
27			investigators	
28	process			
29				
30				
31				
32				
33				
34	Data items	#12	List and define all variables for which data will be sought	7
35			(such as PICO items, funding sources), any pre-planned data	
36			assumptions and simplifications	
37				
38				
39				
40				
41				
42	Outcomes and	#13	List and define all outcomes for which data will be sought,	5
43			including prioritization of main and additional outcomes, with	
44	prioritization		rationale	
45				
46				
47				
48				
49	Risk of bias in	#14	Describe anticipated methods for assessing risk of bias of	8
50			individual studies, including whether this will be done at the	
51	individual studies		outcome or study level, or both; state how this information will	
52			be used in data synthesis	
53				
54				
55				
56				
57				
58				
59				
60				

1	Data synthesis	#15a	Describe criteria under which study data will be quantitatively	7, 8
2			synthesised	
3				
4				
5				
6	Data synthesis	#15b	If data are appropriate for quantitative synthesis, describe	8
7			planned summary measures, methods of handling data and	
8			methods of combining data from studies, including any	
9			planned exploration of consistency (such as I ² , Kendall's τ)	
10				
11				
12				
13				
14				
15				
16	Data synthesis	#15c	Describe any proposed additional analyses (such as	8
17			sensitivity or subgroup analyses, meta-regression)	
18				
19				
20				
21				
22	Data synthesis	#15d	If quantitative synthesis is not appropriate, describe the type	8
23			of summary planned	
24				
25				
26				
27	Meta-bias(es)	#16	Specify any planned assessment of meta-bias(es) (such as	8
28			publication bias across studies, selective reporting within	
29			studies)	
30				
31				
32				
33				
34				
35	Confidence in	#17	Describe how the strength of the body of evidence will be	9
36	cumulative		assessed (such as GRADE)	
37	evidence			
38				
39				
40				
41				

42 The PRISMA-P elaboration and explanation paper is distributed under the terms of the Creative
 43 Commons Attribution License CC-BY. This checklist was completed on 18. February 2022 using
 44 <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with
 45 [Penelope.ai](#)

BMJ Open

Laparoscopic versus open left hemicolectomy for left-sided colon cancer: protocol for a systematic review and meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-062216.R2
Article Type:	Protocol
Date Submitted by the Author:	10-Jun-2022
Complete List of Authors:	Du, Qiang; Sichuan University West China Hospital, Department of Gastrointestinal Surgery Yang, Yang; Sichuan University West China Hospital, Department of Gastrointestinal Surgery Zhang, Jianhao; Sichuan University West China Hospital, Department of Gastrointestinal Surgery Liu, Xueting; Sichuan University West China Hospital, Department of Evidence-Based Medicine and Clinical Epidemiology Wang, Yong; Sichuan University West China Hospital, Department of Gastrointestinal Surgery Yang, Lie; Sichuan University West China Hospital, Department of Gastrointestinal Surgery; Sichuan University West China Hospital, Institute of Digestive Surgery, State Key Laboratory of Biotherapy and Cancer Center
Primary Subject Heading:	Gastroenterology and hepatology
Secondary Subject Heading:	Gastroenterology and hepatology, Surgery
Keywords:	Colorectal surgery < SURGERY, Gastrointestinal tumours < ONCOLOGY, SURGERY

SCHOLARONE™
Manuscripts

1
2
3
4
5
6 **Laparoscopic versus open left hemicolectomy for left-sided colon**
7
8
9 **cancer: protocol for a systematic review and meta-analysis**
10

11
12 Qiang Du^{#1}, Yang Yang^{#1}, Jianhao Zhang¹, Xueting Liu², Yong Wang^{1*}, Lie Yang^{1,3*}
13

14 ¹Department of Gastrointestinal Surgery, West China Hospital of Sichuan University, No. 37
15 Guoxue Lane, Chengdu, 610041, Sichuan Province, China.
16

17
18 ²Department of Evidence-Based Medicine and Clinical Epidemiology, West China Hospital of
19 Sichuan University, No. 37 Guoxue Lane, Chengdu, 610041, Sichuan Province, China.
20

21
22 ³Institute of Digestive Surgery, State Key Laboratory of Biotherapy and Cancer Center, West
23 China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.
24

25
26
27
28 **#Contributed equally to this manuscript.**
29

30
31 ***Corresponding author:**
32

33 Lie Yang, Department of Gastrointestinal Surgery, West China Hospital of Sichuan University,
34 No. 37 Guoxue Lane, Chengdu, 610041, China; Institute of Digestive Surgery, State Key
35 Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu,
36 610041, Sichuan, China; Tel: +86 28 85164035; Fax: +86 28 85164035; E-mail:
37
38 lie_222@163.com.
39
40
41
42

43
44 Yong Wang, Department of Gastrointestinal Surgery, West China Hospital of Sichuan University,
45 No. 37 Guoxue Lane, Chengdu, 610041, China. E-mail :wydoctor1974@aliyun.com.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction: Laparoscopic colectomy has been widely used clinically due to its minimally invasive advantages, and many studies have also demonstrated its safety and efficacy. However, the efficacy of laparoscopic left hemicolectomy remains unclear due to the differences in pathogenesis and surgical details between left and right colon cancers. Therefore, we plan to conduct a systematic review and meta-analysis to investigate whether laparoscopic techniques can be safely used in left hemicolectomy.

Method and analysis: This meta-analysis protocol will be completed and reported according to PRISMA-P (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols) guidelines. A systematic search was performed for all articles related to laparoscopic left hemicolectomy in PubMed, Web of Science, Medline, EMBASE, and the Cochrane Library from inception to November 5, 2021. Article screening and data extraction were performed independently by two authors and cross-checked after completion. The literature to be included will use corresponding tools for bias risk assessment. Subgroup analyses and sensitivity analyses will be used to explore potential heterogeneity.

Ethics and dissemination: Because this systematic review is based on studies with published results and does not involve intervention in patients, no ethical review is required. The results of this study will be published in a peer-reviewed journal.

PROSPERO registration number: CRD42022291526.

Strength and limitations of this study:

To the best of our knowledge, this will be the first meta-analysis to compare surgical approaches for left hemicolectomy.

Subgroup and sensitivity analyses will be used to explore potential heterogeneity.

Both the quality of the included literature and the final outcomes will be evaluated.

Restriction of publication language to English only is a limitation of this study.

INTRODUCTION

Colorectal cancer (CRC) is the third most commonly diagnosed malignant tumor and the third leading cause of tumor-related deaths worldwide. [1 2](#)At present, surgery is still the main treatment for CRC, and laparoscopic surgery has become widely accepted due to its minimally invasive advantages. Although laparoscopic rectal cancer surgery remains controversial, laparoscopic colon cancer surgery has been recommended early by the National Comprehensive Cancer Network (NCCN) guidelines,[3](#) mainly based on several large multicenter RCTs, including the Australasian Laparoscopic Colon Cancer Study (ALCCaS) Trial,[4](#) the Clinical Outcomes of Surgical Therapy (COST) study,[5](#) the Medical Research Council Conventional versus Laparoscopic-Assisted Surgery In Colorectal Cancer (MRC CLASICC) trial and the Colon Cancer Laparoscopic or Open Resection (COLOR) Study.[6 7](#) These trials have demonstrated that laparoscopic colectomy is superior to conventional open surgery in terms of short-term outcomes, such as surgical incision length, intraoperative bleeding, and postoperative functional recovery, while also demonstrating that the adequacy of tumor removal is not threatened and that tumor-related long-term outcomes are not significantly different from those of open surgery.[8-11](#) In addition, these results have also been verified by the Cochrane Database of Systematic Reviews.[12 13](#)

However, left-sided colon cancer has been underrepresented in these trials, as the patients who underwent left hemicolectomy accounted for a very low proportion in the included cases, such as 113 (10.4%) in the COLOR study,[10](#) 59 (7.4%) and 64 (7.4%) in the CLASICC trial and COST study,[5 7](#) respectively, and even fewer in the ALCCaS and Barcelona trials, with only 22 (3.7%) and 5 (2.3%),[11 14](#) respectively. Compared to right hemicolectomy or transverse colectomy, left hemicolectomy has quite different anatomic features and surgical procedures, with a challenge in the mobilization of splenic flexure. Furthermore, it has been widely accepted that right and left colon cancers are two different diseases based on their differences in embryonic origin, genetic characteristics, and biological behaviors and therefore may have different survival outcomes.[15-18](#) Therefore, the safety and prognosis of the treatment of left and right colon cancer should be evaluated separately by site, but the existing clinical trials are not representative of left hemicolectomy, so there is an urgent need to study this topic.

1
2
3
4 At present, several clinical trials have been conducted specifically on laparoscopic left
5 hemicolecotomy,[19 20](#) and even results from RCTs have been published,[21 22](#) but these results
6 lack a pooling to form evidence-based medical evidence. Therefore, the purpose of this study
7 was to synthesize the published results to fill the evidence gap for laparoscopic techniques for
8 left hemicolecotomy and to remind future investigators conducting colon cancer-related studies
9 to stratify the final results based on the different locations of the tumor if there are
10 inconsistencies between the results of this study and those of the whole colon.
11
12
13
14
15
16

17 18 **MATERIALS AND METHODS**

19
20
21 This meta-analysis protocol will be completed and reported according to PRISMA-P (Preferred
22 Reporting Items for Systematic Reviews and Meta-Analyses Protocols) guidelines.[23 24](#)
23 According to the guidelines, our study has been registered on the website of the International
24 Prospective Register of Systematic Reviews (PROSPERO).[25](#) The registration number is
25 CRD42022291526.
26
27
28
29
30
31

32 **Inclusion criteria:**

33
34
35 Population: All patients with left-sided colon cancer confirmed by preoperative imaging and
36 pathology who underwent left hemicolecotomy with mobilization of splenic flexure were the
37 target population of our study.
38
39
40

41
42 Intervention: The intervention in the experimental group was laparoscopic left hemicolecotomy.
43 In this meta-analysis, the definition of left hemicolecotomy mainly included four aspects. First,
44 ligation of the corresponding vessels, such as the inferior mesenteric vein (IMV), was
45 performed. Second, mobilization and pull-down of splenic flexure were observed. Third,
46 resection of the distal transverse colon, splenic flexure, descending colon, sigmoid, etc. Finally,
47 either an intracorporeal anastomosis or an extracorporeal anastomosis is performed for
48 colocolonic anastomosis or colorectal anastomosis. Slight adjustments during the procedure to
49 suit the actual situation are considered acceptable.
50
51
52
53
54
55
56

57
58 Comparison: Traditional open left hemicolecotomy.
59
60

1
2
3
4 Outcome: The outcomes assessed in this systematic review and meta-analysis included
5 perioperative outcomes (operative time, estimated blood loss, length of incision, time to resume
6 oral diet, time to peristalsis), postoperative outcomes (length of hospital stay, number of
7 harvested lymph nodes, 30-day mortality, postoperative complications), and oncological
8 outcomes (tumor recurrence, 5-year overall survival, and 5-year disease-free survival). In this
9 study, 5-year disease-free survival which was defined as the duration from the date of surgery
10 to confirmed recurrence or death from any cause was considered primary outcome, with tumor
11 recurrence, 5-year over survival, perioperative outcomes and postoperative outcomes as
12 secondary outcomes. In this study, tumor recurrence was defined as any recurrence confirmed
13 by imaging or pathology, including local recurrence and systemic recurrence. OS was defined
14 as the duration from the date of surgery to the date of proven death from any cause.
15
16
17
18
19
20
21
22
23
24

25
26 Study design: All randomized controlled and nonrandomized controlled clinical studies
27 comparing laparoscopic left hemicolectomy with open left hemicolectomy for which full text
28 was available were included.
29
30
31

32 **Exclusion criteria:**

- 33 1. Studies that included tumors from other colorectal locations but did not analyse the left
34 hemicolectomy separately or for which data from the left hemicolectomy were not extractable
35 were not included.
 - 36 2. Benign colorectal disease or emergency surgery will be excluded.
 - 37 3. No splenic flexure mobilization will also be excluded.
 - 38 4. Noncomparative studies and non-English publications were excluded.
- 39
40
41
42
43
44
45
46
47

48 **Study Selection**

49
50
51 We systematically searched the PubMed, Web of Science, Medline, EMBASE, and Cochrane
52 Library databases for all literature comparing laparoscopic and open surgical approaches for
53 left hemicolectomy from inception to November 5, 2021. Searches were carried out using
54 medical subject headings (MeSH) and free text words in combination with the search strategy.
55 We used the following keywords: “colon cancer”, “left hemicolectomy”, “laparoscopy” and
56
57
58
59
60

“open”. All possible forms of these keywords will be used to ensure the comprehensiveness of the search. Additionally, we enriched our retrieval results with several methods, such as the similar articles function in PubMed, cross-checking references of the retrieved literature, searching ClinicalTrials (<https://www.clinicaltrials.gov/>), etc.

Search Terms for PubMed

#1 (((((((((((((((((((Colonic Neoplasms) OR (Neoplasm, Colonic)) OR (Neoplasms, Colonic)) OR (Colon Neoplasms)) OR (Colon Neoplasm)) OR (Neoplasm, Colon)) OR (Neoplasms, Colon)) OR (Cancer of Colon)) OR (Colon Cancers)) OR (Colon Cancer)) OR (Cancer, Colon)) OR (Cancers, Colon)) OR (Cancer of the Colon)) OR (Colonic Cancer)) OR (Cancer, Colonic)) OR (Cancers, Colonic)) OR (Colonic Cancers)) OR (Colon Adenocarcinoma)) OR (Adenocarcinoma, Colon)) OR (Adenocarcinomas, Colon)) OR (Colon Adenocarcinomas)

#2 open surgery

#3 (((((((((((((((((((Laparoscopy) OR (Celioscopy)) OR (Peritoneoscopy)) OR (Surgical Procedures, Laparoscopic)) OR (Laparoscopic Surgical Procedure)) OR (Procedure, Laparoscopic Surgical)) OR (Procedures, Laparoscopic Surgical)) OR (Surgery, Laparoscopic)) OR (Laparoscopic Surgical Procedures)) OR (Laparoscopic Surgery)) OR (Laparoscopic Surgeries)) OR (Surgeries, Laparoscopic)) OR (Laparoscopic Assisted Surgery)) OR (Laparoscopic Assisted Surgeries)) OR (Surgeries, Laparoscopic Assisted)) OR (Surgery, Laparoscopic Assisted)) OR (Surgical Procedure, Laparoscopic)

#4 (left hemicolectomy) OR (left colectomy)

#5 #2 AND #3

#6 #1 AND #4 AND #5

The management of the literature search records will be carried out in EndNote X9.1. Two authors (QD and JZ) independently performed an initial screening of the titles and abstracts of the search results and assessed the eligibility of the articles. After removing duplicates and irrelevant literature, the two authors will assess the eligibility of the articles according to the inclusion criteria after reading the full text of the remaining articles separately. Any controversial points arising during this process will be referred to a third author (LY) and

1
2
3
4 discussed until the dispute is resolved. The specific literature screening process will be
5 summarized in a flow diagram.
6
7

8 **Data Extraction**

9
10
11 Data to be collected, such as study details (first author, year of publication, study design, follow-
12 up period, type of outcome), patient demographics (age, sex, American Society of
13 Anesthesiologists (ASA) score, tumor stage, etc.), and the outcomes of interest mentioned
14 above will be consolidated into a piloting spreadsheet. Additionally, we will extract the effect
15 estimates of the outcome of interest for statistical analysis. If there were multiple
16 representations of the data, we preferred to use the data after adjusting for confounding factors.
17
18 To reduce bias and reduce errors in data extraction, the same two investigators (QD and JZ)
19 independently extracted data from the included literature, cross-checked after extraction, and
20 disagreements were resolved by discussion and, if necessary, by asking a third author (LY) to
21 resolve. Because this analysis was based on the intention-to-treat principle, all patients who
22 were converted from the laparoscopic group to the conventional open surgery group remained
23 in the laparoscopic group for analysis. We will also use sensitivity analyses to assess the impact
24 of including studies that do not report intention-to-treat on overall outcomes.
25
26

27
28 There are currently several RCTs, such as COST, CLASICC, ALCCaS, and COLOR,
29 comparing laparoscopic and open colectomy, and we believe that inclusion of their data would
30 enhance the quality of our evidence for this study. We will be sending emails to the authors of
31 these trials asking for stratified data on left hemicolectomy. Meanwhile, for the missing data
32 of other studies, we will also send an email to ask for.
33
34
35
36
37

38 **Statistical Analysis**

39
40 Statistically, it is not possible to combine the median with the mean value, and only data
41 expressed as the mean and standard deviation can be used for meta-analysis. In this study, we
42 will not use the median to estimate the mean, as other studies have done, because we believe
43 this would not be worth the cost. The weighted mean difference (WMD) or standardized mean
44 difference (SMD) and corresponding 95% confidence interval (CI) were used for the analysis
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 of continuous variables. The dichotomous variables were analysed using risk ratio (RR) values
5 with 95% CIs. Considering the characteristics of survival analysis, we will first attempt to
6 extract survival analysis-related data from the included studies and then calculate the pooled
7 hazard ratio (HR). HR and 95% CI will be extracted directly from the article, and if not reported
8 in the article, we consider using software such as Engauge Digitizer to obtain the required data
9 from Kaplan–Meier curves following the method provided by Parmar et al.²⁶ Finally, the
10 obtained data will be integrated into the spreadsheet designed by Tierney et al. to calculate the
11 HR and 95% CI.²⁷ If the data were insufficient or the HR was not available for other reasons,
12 then the pooled OR values of OS and DFS were calculated separately.

21
22 Statistical heterogeneity among the studies was calculated by the chi-squared (χ^2) test and I-
23 squared (I^2) test.²⁸ We considered that high heterogeneity existed if the value of $P < 0.1$ or $I^2 >$
24 50%. When the heterogeneity was 0, the fixed-effects model was used, and when the
25 heterogeneity was between 0-50%, the random-effects model was used. We will conduct
26 subgroup analyses, based on different study design types, and meta-regression so that we can
27 explore the potential causes of heterogeneity and reduce it as accurately as possible when
28 heterogeneity exceeded 50%. If the heterogeneity is too high, then qualitative analysis was
29 performed. Sensitivity analysis will be performed to determine the robustness of the results by
30 sequentially excluding one study at a time. $P < 0.05$ was considered statistically significant.
31 Software such as RevMan 5.4 and STATA 16 will be used for statistical processing. Publication
32 bias will be estimated by visual assessment of funnel plots if ≥ 10 studies are available. If the
33 extracted data are not suitable for pooling, a systematic narrative synthesis will be presented in
34 textual form.

48 **Risk Of Bias Assessment**

51
52 Quality assessment will be carried out by two authors (QD and JZ), and discrepancies will be
53 resolved through discussion. If consensus was not reached, then the third author (LY) was
54 consulted for arbitration. The risk of bias in randomized controlled trials will be assessed using
55 the Cochrane Risk of Bias Tool,²⁹ which includes six aspects: randomization, allocation
56 concealment, application of blinding, integrity of outcome data, selective reporting, and other
57
58
59
60

1
2
3
4 biases. For each, we will use high risk, low risk, or unclear risk to assess the results. The
5
6 methodological quality of nonrandomized controlled trials will be evaluated using the
7
8 Newcastle–Ottawa Scale (NOS),³⁰ which consists of three aspects: patient selection,
9
10 comparability of cohorts, and assessment of outcome. The total score is 9 stars, and each article
11
12 is classified as low quality (0-5 stars) or high quality (6-9 stars). The final results will be
13
14 summarized in a table.

15 16 **Evidence Quality Evaluation**

17
18
19 The quality of evidence for each outcome will be evaluated using the Grading of
20
21 Recommendations Assessment, Development and Evaluation (GRADE) system,³¹ with four
22
23 levels: high, moderate, low, and very low.
24
25

26 27 **Patient And Public Involvement**

28
29
30 Since this study is a secondary study based on other studies, there will be no direct patient or
31
32 public involvement in this study.
33
34

35 36 **Ethics And Dissemination**

37
38 Because no patients were involved, ethical approval was not required. The final results of this
39
40 research will be submitted to a peer-reviewed journal or presented at relevant conferences, and
41
42 any deviations from this protocol will be recorded and explained in the final report.
43
44
45

46
47 **Contributors:** The original idea was conceived by LY. QD and YY drafted the manuscript for
48
49 this protocol. QD, YY, JHZ, YW, LY participated in the design of the study and the setting of the
50
51 inclusion and exclusion criteria. QD and YY design the search strategy, and XTL will be
52
53 responsible for the modifications. QD and JHZ will perform the literature screening and data
54
55 extraction. YW and LY will review the overall work. All authors have read and approved the
56
57 publication of the protocol.
58
59

60 **Funding:** This work was supported by Wu Jieping Medical Foundation (No.312180452).

1
2
3
4 **Competing interests:** None declared.
5

6 **Ethical approval:** Not required.
7

8
9 **Patient consent for publication:** Not required.
10

11 **Provenance and peer review:** Not commissioned; externally peer reviewed.
12

13
14 **Open access:** This is an open access article distributed in accordance with the Creative Commons
15 Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix,
16 adapt, build upon this work non-commercially, and license their derivative works on different
17 terms, provided the original work is properly cited, appropriate credit is given, any changes made
18 indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.
19
20
21
22

23 **ORCID iDs**

24
25
26
27 Qiang Du: <https://orcid.org/0000-0002-7283-1140>
28

29
30 Lie Yang: <https://orcid.org/0000-0003-1178-7147>
31

32 **Word count** 2102
33

34 **REFERENCES**

- 35
36
37
38 1. Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021. *CA Cancer J Clin* 2021;71(1):7-33.
39 doi: 10.3322/caac.21654 [published Online First: 2021/01/13]
40
41 2. Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020. *CA Cancer J Clin*
42 2020;70(3):145-64. doi: 10.3322/caac.21601 [published Online First: 2020/03/07]
43
44 3. Benson AB, Venook AP, Al-Hawary MM, et al. Colon Cancer, Version 2.2021, NCCN Clinical
45 Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2021;19(3):329-59. doi:
46 10.6004/jnccn.2021.0012 [published Online First: 2021/03/17]
47
48 4. Hewett PJ, Allardyce RA, Bagshaw PF, et al. Short-Term Outcomes of the Australasian Randomized
49 Clinical Study Comparing Laparoscopic and Conventional Open Surgical Treatments for Colon
50 Cancer. *Annals of Surgery* 2008;248(5):728-38. doi: 10.1097/SLA.0b013e31818b7595
51
52 5. Clinical Outcomes of Surgical Therapy Study G, Nelson H, Sargent DJ, et al. A comparison of
53 laparoscopically assisted and open colectomy for colon cancer. *N Engl J Med*
54 2004;350(20):2050-9. doi: 10.1056/NEJMoa032651 [published Online First: 2004/05/14]
55
56 6. Veldkamp R, Kuhry E, Hop WC, et al. Laparoscopic surgery versus open surgery for colon cancer:
57 short-term outcomes of a randomised trial. *Lancet Oncol* 2005;6(7):477-84. doi:
58 10.1016/S1470-2045(05)70221-7 [published Online First: 2005/07/05]
59
60 7. Guillou PJ, Quirke P, Thorpe H, et al. Short-term endpoints of conventional versus laparoscopic-

- 1
2
3 assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre,
4 randomised controlled trial. *The Lancet* 2005;365(9472):1718-26. doi: 10.1016/s0140-
5 6736(05)66545-2
6
7
8 8. Stucky CC, Pockaj BA, Novotny PJ, et al. Long-term follow-up and individual item analysis of quality
9 of life assessments related to laparoscopic-assisted colectomy in the COST trial 93-46-53 (INT
10 0146). *Ann Surg Oncol* 2011;18(9):2422-31. doi: 10.1245/s10434-011-1650-2 [published
11 Online First: 2011/04/01]
12
13 9. Jayne DG, Thorpe HC, Copeland J, et al. Five-year follow-up of the Medical Research Council
14 CLASICC trial of laparoscopically assisted versus open surgery for colorectal cancer. *Br J Surg*
15 2010;97(11):1638-45. doi: 10.1002/bjs.7160 [published Online First: 2010/07/16]
16
17 10. Colon Cancer Laparoscopic or Open Resection Study G, Buunen M, Veldkamp R, et al. Survival
18 after laparoscopic surgery versus open surgery for colon cancer: long-term outcome of a
19 randomised clinical trial. *Lancet Oncol* 2009;10(1):44-52. doi: 10.1016/S1470-2045(08)70310-
20 3 [published Online First: 2008/12/17]
21
22 11. Bagshaw PF, Allardyce RA, Frampton CM, et al. Long-term outcomes of the australasian randomized
23 clinical trial comparing laparoscopic and conventional open surgical treatments for colon cancer:
24 the Australasian Laparoscopic Colon Cancer Study trial. *Ann Surg* 2012;256(6):915-9. doi:
25 10.1097/SLA.0b013e3182765ff8 [published Online First: 2012/11/17]
26
27 12. Schwenk W, Haase O, Neudecker J, et al. Short term benefits for laparoscopic colorectal resection.
28 *Cochrane Database Syst Rev* 2005(3):CD003145. doi: 10.1002/14651858.CD003145.pub2
29 [published Online First: 2005/07/22]
30
31 13. Kuhry E, Schwenk WF, Gaupset R, et al. Long-term results of laparoscopic colorectal cancer
32 resection. *Cochrane Database Syst Rev* 2008(2):CD003432. doi:
33 10.1002/14651858.CD003432.pub2 [published Online First: 2008/04/22]
34
35 14. Lacy AM, Delgado S, Castells A, et al. The long-term results of a randomized clinical trial of
36 laparoscopy-assisted versus open surgery for colon cancer. *Ann Surg* 2008;248(1):1-7. doi:
37 10.1097/SLA.0b013e31816a9d65 [published Online First: 2008/06/27]
38
39 15. Meguid RA, Slidell MB, Wolfgang CL, et al. Is there a difference in survival between right- versus
40 left-sided colon cancers? *Ann Surg Oncol* 2008;15(9):2388-94. doi: 10.1245/s10434-008-0015-
41 y [published Online First: 2008/07/16]
42
43 16. Gervaz P, Bucher P, Morel P. Two colons-two cancers: paradigm shift and clinical implications. *J*
44 *Surg Oncol* 2004;88(4):261-6. doi: 10.1002/jso.20156 [published Online First: 2004/11/27]
45
46 17. Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal
47 tumor location. *Ann Intern Med* 1990;113(10):779-88. doi: 10.7326/0003-4819-113-10-779
48 [published Online First: 1990/11/15]
49
50 18. Benedix F, Kube R, Meyer F, et al. Comparison of 17,641 patients with right- and left-sided colon
51 cancer: differences in epidemiology, perioperative course, histology, and survival. *Dis Colon*
52 *Rectum* 2010;53(1):57-64. doi: 10.1007/DCR.0b013e3181c703a4 [published Online First:
53 2009/12/17]
54
55 19. Desiderio J, Trastulli S, Ricci F, et al. Laparoscopic versus open left colectomy in patients with
56 sigmoid colon cancer: prospective cohort study with long-term follow-up. *Int J Surg*
57 2014;12(8):745-50. doi: 10.1016/j.ijssu.2014.05.074 [published Online First: 2014/06/03]
58
59 20. Hsu YJ, Chern YJ, Jhuang JR, et al. Efficient and Safe Method for Splenic Flexure Mobilization in
60 Laparoscopic Left Hemicolectomy: A Propensity Score-weighted Cohort Study. *Surg Laparosc*

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Endosc Percutan Tech* 2020;31(2):196-202. doi: 10.1097/SLE.0000000000000884 [published Online First: 2020/12/08]
21. Braga M, Frasson M, Zuliani W, et al. Randomized clinical trial of laparoscopic versus open left colonic resection. *Br J Surg* 2010;97(8):1180-6. doi: 10.1002/bjs.7094 [published Online First: 2010/07/06]
22. Liang JT, Huang KC, Lai HS, et al. Oncologic results of laparoscopic versus conventional open surgery for stage II or III left-sided colon cancers: a randomized controlled trial. *Ann Surg Oncol* 2007;14(1):109-17. doi: 10.1245/s10434-006-9135-4 [published Online First: 2006/10/27]
23. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4:1. doi: 10.1186/2046-4053-4-1 [published Online First: 2015/01/03]
24. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ* 2015;350:g7647. doi: 10.1136/bmj.g7647 [published Online First: 2015/01/04]
25. Booth A, Clarke M, Dooley G, et al. The nuts and bolts of PROSPERO: an international prospective register of systematic reviews. *Syst Rev* 2012;1:2. doi: 10.1186/2046-4053-1-2 [published Online First: 2012/05/17]
26. Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. *Statistics in Medicine* 1998;17(24):2815-34. doi: 10.1002/(sici)1097-0258(19981230)17:24<2815::Aid-sim110>3.0.Co;2-8
27. Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. *Trials* 2007;8:16. doi: 10.1186/1745-6215-8-16 [published Online First: 2007/06/09]
28. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ* 2003;327(7414):557-60. doi: 10.1136/bmj.327.7414.557 [published Online First: 2003/09/06]
29. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011;343:d5928. doi: 10.1136/bmj.d5928 [published Online First: 2011/10/20]
30. GA Wells, B Shea, D O'Connell, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp accessed February 11 2022.
31. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;336(7650):924-6. doi: 10.1136/bmj.39489.470347.AD [published Online First: 2008/04/26]

Reporting checklist for protocol of a systematic review and meta analysis.

Based on the PRISMA-P guidelines.

			Page
		Reporting Item	Number
Title			
Identification	#1a	Identify the report as a protocol of a systematic review	1
Update	#1b	If the protocol is for an update of a previous systematic review, identify as such	n/a
Registration			
	#2	If registered, provide the name of the registry (such as PROSPERO) and registration number	2
Authors			
Contact	#3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contribution	#3b	Describe contributions of protocol authors and identify the guarantor of the review	10
Amendments			
	#4	If the protocol represents an amendment of a previously	n/a

completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments

Support

Sources	#5a	Indicate sources of financial or other support for the review	10
Sponsor	#5b	Provide name for the review funder and / or sponsor	10
Role of sponsor or funder	#5c	Describe roles of funder(s), sponsor(s), and / or institution(s), if any, in developing the protocol	10

Introduction

Rationale	#6	Describe the rationale for the review in the context of what is already known	3
Objectives	#7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	4, 5

Methods

Eligibility criteria	#8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	4, 5
Information sources	#9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	5

1	Search strategy	#10	Present draft of search strategy to be used for at least one	6
2			electronic database, including planned limits, such that it	
3			could be repeated	
4				
5				
6				
7				
8	Study records -	#11a	Describe the mechanism(s) that will be used to manage	6
9			records and data throughout the review	
10	data management			
11				
12				
13				
14	Study records -	#11b	State the process that will be used for selecting studies (such	6
15			as two independent reviewers) through each phase of the	
16	selection process		review (that is, screening, eligibility and inclusion in meta-	
17			analysis)	
18				
19				
20				
21				
22				
23				
24	Study records -	#11c	Describe planned method of extracting data from reports	7
25			(such as piloting forms, done independently, in duplicate),	
26	data collection		any processes for obtaining and confirming data from	
27			investigators	
28	process			
29				
30				
31				
32				
33				
34	Data items	#12	List and define all variables for which data will be sought	7
35			(such as PICO items, funding sources), any pre-planned data	
36			assumptions and simplifications	
37				
38				
39				
40				
41				
42	Outcomes and	#13	List and define all outcomes for which data will be sought,	5
43			including prioritization of main and additional outcomes, with	
44	prioritization		rationale	
45				
46				
47				
48				
49	Risk of bias in	#14	Describe anticipated methods for assessing risk of bias of	8
50			individual studies, including whether this will be done at the	
51	individual studies		outcome or study level, or both; state how this information will	
52			be used in data synthesis	
53				
54				
55				
56				
57				
58				
59				
60				

1	Data synthesis	#15a	Describe criteria under which study data will be quantitatively synthesised	7, 8
2				
3				
4				
5				
6	Data synthesis	#15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I ² , Kendall's τ)	8
7				
8				
9				
10				
11				
12				
13				
14				
15				
16	Data synthesis	#15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	8
17				
18				
19				
20				
21				
22	Data synthesis	#15d	If quantitative synthesis is not appropriate, describe the type of summary planned	8
23				
24				
25				
26				
27	Meta-bias(es)	#16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	8
28				
29				
30				
31				
32				
33				
34				
35	Confidence in	#17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	9
36	cumulative			
37	evidence			
38				
39				
40				
41				

The PRISMA-P elaboration and explanation paper is distributed under the terms of the Creative Commons Attribution License CC-BY. This checklist was completed on 18. February 2022 using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)